Japanese Research Collaboration on Measurement of Exosomes in Blood from Cancer Patients

The National Cancer Center Japan , JVCKENWOOD Corporation, Sysmex Corporation and Daiichi Sankyo Company Limited announced today that they have commenced collaborative research with the aim of raising the quality of cancer diagnosis and treatment. The collaborative research will target exosomes, a microparticle released from tissues.

It has been demonstrated in recent years that cancer patients have high levels of cancer-specific exosomes in their blood. The collaborative research aims to detect such cancer-specific exosomes (for instance, HER2 protein expressing exosome) from patient blood. The research is expected to provide a new option for patients to make decision for cancer therapy and evaluating drug treatment outcomes from blood, in addition to current tumor tissue sampling approach.

Regarding individual roles in the collaborative research, JVCKENWOOD will build technologies that detect cancer-specific exosomes by using its exosome measurement device. Sysmex will evaluate the device created by JVCKENWOOD and will apply its proprietary gene and protein measurement technologies toward clinical use. National Cancer Center and Daiichi Sankyo will make effective use of exosome measurement data in improving the diagnosis and treatment of cancer patients.

The research collaboration among a specialist cancer research organization, diagnostic and electronic device manufacturers and a pharmaceutical company makes it possible to establish this new technology for exosome measurement in clinical use. As a result, this exosome measurement is expected not only to greatly reduce the stress of patients by avoiding multiple tissue biopsies, but also to provide new therapeutic opportunities to patients in whom the sampling of lesion tissue is difficult.

Source – NCC Japan

Leave a Reply

Your email address will not be published. Required fields are marked *

*